Antifibrinolytic Drugs Market, By Type (Tranexamic Acid, Aminocaproic Acid, Aprotinin, Lysteda, RiaSTAP, Fibrinogen, Trasylol, and Amicor), By Indication, By End Use, By Form, By Country, and By Region Global Industry Analysis, Market Size, Market Share & Forecast from 2026-2033
|
Report ID
AV5001
|
Published Date
April 2026
|
Pages
288
|
Industry
Healthcare
|
|
|
Base Year
2025
|
Historical Data
2019-2024
|
Delivery Timeline
24 Hour
|
REPORT HIGHLIGHT
Antifibrinolytic Drugs Market size was valued at US$ 42,061.87 Million in 2025, expanding at a CAGR of 7.99% from 2026 to 2033.
Antifibrinolytic drugs are medications that promote blood clot formation and prevent clots from breaking down too quickly. They work by inhibiting the activation of plasminogen, thereby stabilizing fibrin clots. These drugs are widely used to manage conditions associated with excessive bleeding, including heavy menstrual bleeding, vascular tumors, and hemorrhagic disorders. They are also commonly administered during and after surgical procedures to control bleeding. Key antifibrinolytic agents include tranexamic acid, aprotinin, aminocaproic acid, and other serine protease inhibitors. Their applications extend to managing bleeding in areas such as the oral cavity, nasal passages, gastrointestinal tract, and uterus, making them essential in hospitals, clinics, and surgical centers.
The antifibrinolytic drugs market comprises therapies designed to reduce excessive bleeding by preventing fibrin degradation and maintaining clot stability. Market growth is driven by the rising incidence of hemorrhagic conditions, heavy menstrual bleeding, and vascular disorders, along with increasing demand for effective bleeding control in surgical and trauma care settings. For example, in February 2025, data from the U.S. government indicated that approximately 10% of women experience heavy menstrual bleeding, characterized by prolonged or unusually heavy periods that can significantly impact daily life. Menstrual cycles lasting longer than five to seven days or involving blood loss exceeding 80 mL per cycle may lead to iron deficiency and anemia. These statistics highlight the widespread prevalence and health impact of heavy menstrual bleeding, underscoring the need for effective antifibrinolytic treatments and greater awareness to improve patient outcomes.
Antifibrinolytic Drugs Market- Market Dynamics
Rising Availability of Generic Antifibrinolytic Drugs to Drive Market Growth
Rising Availability of Generic Antifibrinolytic Drugs to Drive MarkeThe increasing availability of generic antifibrinolytic medications, particularly tranexamic acid, is contributing significantly to market growth by improving affordability and expanding access across hospitals, surgical centers, and emergency care settings. Lower-cost generic options make these treatments more accessible, especially in low- and middle-income regions. Additionally, the presence of multiple manufacturers helps ensure a consistent supply and supports national healthcare programs, particularly in trauma and obstetric care. For example, in June 2024, Avenacy announced the U.S. launch of its FDA-approved Tranexamic Acid Injection, USP, a generic version of Cyklokapron. This product is intended for short-term use in patients with hemophilia to reduce or prevent bleeding and to minimize the need for replacement therapy during and after dental procedures. Such developments underscore the growing importance of generic medications in enhancing patient access and improving bleeding management worldwide.t Growth
Antifibrinolytic Drugs Market- Segmentation Analysis:
The Global Antifibrinolytic Drugs Market is segmented on the basis of Type, Indication, End Use, Form, and Region.
Under the product type segment, tranexamic acid holds a significant share of the antifibrinolytic drugs market due to its widespread use in managing excessive bleeding across a variety of medical conditions. Other antifibrinolytic agents, including aminocaproic acid, aprotinin, and fibrinogen, are also increasingly adopted to control bleeding during surgeries, trauma care, and gynecological procedures. Growing awareness among healthcare providers and patients about the efficacy and benefits of these drugs has further boosted their preference over alternative therapies, driving market demand. For example, a report by the NHS Confederation highlights that the economic cost of absenteeism due to severe menstrual pain, heavy periods, endometriosis, fibroids, and ovarian cysts is nearly $14.7 billion annually in England alone. Additionally, approximately 60,000 women are out of employment due to menopause-related symptoms, resulting in an economic impact of around $2.01 billion per year. The report also notes that investing an additional $1.34 per woman in obstetrics and gynecology services could yield a return of $14.74, underscoring the significant social and economic benefits of effective gynecological care. These factors emphasize the growing clinical and market importance of antifibrinolytic drugs in gynecology.
By indication, the antifibrinolytic drugs market is segmented into gynecology, hereditary angioedema, fibrinolytic testing, surgeries, and other applications, each addressing specific medical needs. Gynecology and surgical procedures represent major segments due to their critical role in controlling heavy bleeding and blood loss, while hereditary angioedema and fibrinolytic testing cater to specialized patient populations. For instance, in December 2025, the UK Haemophilia Centre Doctors’ Organisation (UKHCDO) registry recorded 42,691 individuals with a bleeding disorder in the UK, including 9,999 with hemophilia A (including carriers), 2,237 with hemophilia B (including carriers), and 12,825 with von Willebrand disease. These numbers represent an increase compared with previous years, reflecting improvements in diagnosis, patient care, and data reporting across hemophilia centers. The registry highlights the extensive engagement of healthcare services in managing bleeding disorders, further supporting the demand for targeted antifibrinolytic therapies.
Antifibrinolytic Drugs Market- Geographical Insights
Geopolitical factors can influence the antifibrinolytic drugs market by creating trade disruptions and supply chain challenges, potentially restricting access to critical raw materials and affecting the production and distribution of essential medications.
In North America, the market accounts for a significant share due to the widespread use of antifibrinolytic drugs in surgical and trauma care. The high prevalence of surgical procedures, coupled with an aging population requiring frequent interventions, has driven demand for medications that help prevent excessive blood loss. For example, in 2023, the ISAPS reported nearly 34.9 million cosmetic procedures performed worldwide, a 3.4% increase compared with 2022. Of these, approximately 15.8 million were surgical procedures and 19.1 million were non-surgical, demonstrating broad adoption of aesthetic treatments globally. Face and head procedures exceeded 6.5 million, representing a 19.6% increase from the previous year, while injectable treatments, such as botulinum toxin, reached around 8.9 million. These trends underscore the growing role of medical procedures in driving demand for specialized drugs and healthcare solutions.
The Asia Pacific region is projected to experience significant growth, fueled by increasing awareness of blood management in surgeries and trauma care. Countries like China and India are expected to see a rise in surgical procedures as healthcare infrastructure expands and access to advanced medical facilities improves. In 2024, China’s healthcare system continued to grow, with over 1 million medical and health institutions nationwide, reflecting steady infrastructure development. According to the National Health Commission, the country recorded more than 9 billion medical and health service visits annually, highlighting rising healthcare demand. Additionally, the healthcare workforce continues to expand, with over 4.7 million licensed assistant physicians and more than 5.6 million registered nurses. These factors collectively support the increasing adoption of antifibrinolytic drugs across the region.
South Korea Foaming Creamer Market- Country Insights
Among individual countries, China is experiencing significant growth in the adoption of antifibrinolytic drugs, driven by rising surgical volumes and expanding maternal health programs. The increasing number of inpatient surgeries reflects a strong demand for effective blood management solutions. Additionally, the growing prevalence of chronic blood disorders, such as hemophilia, further supports the need for antifibrinolytic therapies.
For example, over the past decade, China has made substantial progress in reducing premature mortality from major chronic diseases, decreasing the rate from 18.5% in 2015 to 15% in 2023—a nearly 19% reduction. Despite this improvement, chronic diseases continue to account for over 80% of total annual deaths, underscoring their significant health burden. To address these challenges, China has established 488 national demonstration areas for chronic disease prevention, covering approximately 17.1% of county-level regions, alongside expanded screening programs and health promotion initiatives. These developments in healthcare infrastructure and public health strategies are expected to sustain strong demand for advanced bleeding management therapies, including antifibrinolytic drugs.
Antifibrinolytic Drugs Market- Competitive Landscape:
Major players in the antifibrinolytic drugs market are prioritizing innovation and strategic initiatives to enhance their market presence. They invest heavily in research and development to improve drug formulations and optimize outcomes for patients with bleeding disorders. Collaborations with hospitals and clinical institutions help drive adoption and build credibility, while expansion into emerging markets further supports growth. Key companies in the market include ACIC Pharmaceuticals Inc., Akorn Inc., Aurobindo Pharma Limited, Novartis AG, Pfizer Inc., and Vitruvias Therapeutics Inc. For example, in January 2023, Pfizer partnered with a biotechnology firm to develop advanced antifibrinolytic drug formulations aimed at reducing postoperative bleeding complications. This collaboration enhances therapeutic options for surgical and trauma patients, addressing the growing demand for effective bleeding management solutions in critical care.
Recent Developments:
- January 2025: Novartis AG announced an agreement to acquire Anthos Therapeutics for approximately $925 million, strengthening its late-stage cardiovascular and hemostasis drug pipeline.
- September 2023: ACIC Pharmaceuticals Inc., in partnership with Methapharm, Inc. and Bioindustria Laboratorio Italiano Medicinali S.p.A., filed FDA registrations for tranexamic acid, advancing its commercialization efforts in the U.S. antifibrinolytic market.
SCOPE OF THE REPORT
The scope of this report covers the market by its major segments, which include as follows:
GLOBAL ANTIFIBRINOLYTIC DRUGS MARKET KEY PLAYERS- DETAILED COMPETITIVE INSIGHTS
- Pfizer Inc.
- Novartis AG
- Sanofi SA
- Takeda Pharmaceutical Company Limited
- Viatris Inc.
- Bayer AG
- Aurobindo Pharma Limited
- Ferring Pharmaceuticals
- Zydus Lifesciences Limited
- ACIC Pharmaceuticals Inc.
- Johnson & Johnson (Ethicon – surgical bleeding control)
- Octapharma AG
- Apotex Inc.
- Aspen Pharmacare Holdings Limited
- Cipla Limited
- Others
GLOBAL ANTIFIBRINOLYTIC DRUGS MARKET, BY TYPE- MARKET ANALYSIS, 2020 - 2033
- Tranexamic Acid
- Aminocaproic Acid
- Aprotinin
- Lysteda
- RiaSTAP
- Fibrinogen
- Trasylol
- Amicor
- Others
GLOBAL ANTIFIBRINOLYTIC DRUGS MARKET, BY INDICATION- MARKET ANALYSIS, 2020 - 2033
- Surgeries
- Gynaecology
- Hereditary Angioedema
- Fibrinolytic Response Testing
- Others
GLOBAL ANTIFIBRINOLYTIC DRUGS MARKET, BY END USE- MARKET ANALYSIS, 2020 - 2033
- Clinics
- Hospitals
- Ambulatory Surgery Centres
- Health Care Specialty Processes
- Others
GLOBAL ANTIFIBRINOLYTIC DRUGS MARKET, BY FORM- MARKET ANALYSIS, 2020 - 2033
- Injectable
- Oral
- Others
GLOBAL ANTIFIBRINOLYTIC DRUGS MARKET, BY REGION- MARKET ANALYSIS, 2020 - 2033
North America
- U.S.
- Canada
Europe
- Germany
- UK
- France
- Italy
- Spain
- The Netherlands
- Sweden
- Russia
- Poland
- Rest of Europe
Asia Pacific
- China
- India
- Japan
- South Korea
- Australia
- Indonesia
- Thailand
- Philippines
- Rest of APAC
Latin America
- Brazil
- Mexico
- Argentina
- Colombia
- Rest of LATAM
The Middle East and Africa
- Saudi Arabia
- UAE
- Israel
- Turkey
- Algeria
- Egypt
- Rest of MEA
TABLE OF CONTENT
1. Antifibrinolytic Drugs Market Overview
1.1. Study Scope
1.2. Market Estimation Years
2. Executive Summary
2.1. Market Snippet
2.1.1. Antifibrinolytic Drugs Market Snippet by Type
2.1.2. Antifibrinolytic Drugs Market Snippet by Indication
2.1.3. Antifibrinolytic Drugs Market Snippet by End Use
2.1.4. Antifibrinolytic Drugs Market Snippet by Form
2.1.5. Antifibrinolytic Drugs Market Snippet by Country
2.1.6. Antifibrinolytic Drugs Market Snippet by Region
2.2. Competitive Insights
3. Antifibrinolytic Drugs Key Market Trends
3.1. Antifibrinolytic Drugs Market Drivers
3.1.1. Impact Analysis of Market Drivers
3.2. Antifibrinolytic Drugs Market Restraints
3.2.1. Impact Analysis of Market Restraints
3.3. Antifibrinolytic Drugs Market Opportunities
3.4. Antifibrinolytic Drugs Market Future Trends
4. Antifibrinolytic Drugs Industry Study
4.1. PEST Analysis
4.2. Porter’s Five Forces Analysis
4.3. Growth Prospect Mapping
4.4. Regulatory Framework Analysis
5. Antifibrinolytic Drugs Market: Impact of Escalating Geopolitical Tensions
5.1. Impact of COVID-19 Pandemic
5.2. Impact of Russia-Ukraine War
5.3. Impact of Middle East Conflicts
6. Antifibrinolytic Drugs Market Landscape
6.1. Antifibrinolytic Drugs Market Share Analysis, 2025
6.2. Breakdown Data, by Key Manufacturer
6.2.1. Established Players’ Analysis
6.2.2. Emerging Players’ Analysis
7. Antifibrinolytic Drugs Market – By Type
7.1. Overview
7.1.1. Segment Share Analysis, By Type, 2025 & 2033 (%)
7.1.2. Tranexamic Acid
7.1.3. Aminocaproic Acid
7.1.4. Aprotinin
7.1.5. Lysteda
7.1.6. RiaSTAP
7.1.7. Fibrinogen
7.1.8. Trasylol
7.1.9. Amicor
7.1.10. Others
8. Antifibrinolytic Drugs Market – By Indication
8.1. Overview
8.1.1. Segment Share Analysis, By Indication, 2025 & 2033 (%)
8.1.2. Surgeries
8.1.3. Gynaecology
8.1.4. Hereditary Angioedema
8.1.5. Fibrinolytic Response Testing
8.1.6. Others
9. Antifibrinolytic Drugs Market – By End Use
9.1. Overview
9.1.1. Segment Share Analysis, By End Use, 2025 & 2033 (%)
9.1.2. Clinics
9.1.3. Hospitals
9.1.4. Ambulatory Surgery Centres
9.1.5. Health Care Specialty Processes
10. Antifibrinolytic Drugs Market – By Form
10.1. Overview
10.1.1. Segment Share Analysis, By Indication, 2025 & 2033 (%)
10.1.2. Injectable
10.1.3. Oral
11. Antifibrinolytic Drugs Market – By Geography
11.1. Introduction
11.1.1. Segment Share Analysis, By Geography, 2025 & 2033 (%)
11.2. North America
11.2.1. Overview
11.2.2. Antifibrinolytic Drugs Key Manufacturers in North America
11.2.3. North America Market Size and Forecast, By Country, 2020 - 2033 (US$ Million)
11.2.4. North America Market Size and Forecast, By Type, 2020 - 2033 (US$ Million)
11.2.5. North America Market Size and Forecast, By Indication, 2020 - 2033 (US$ Million)
11.2.6. North America Market Size and Forecast, By End Use, 2020 - 2033 (US$ Million)
11.2.7. North America Market Size and Forecast, By Form, 2020 - 2033 (US$ Million)
11.2.8. U.S.
11.2.8.1. Overview
11.2.8.2. Market Analysis, Forecast, and Y-O-Y Growth Rate, 2020 - 2033, (US$ Million)
11.2.8.3. U.S. Market Size and Forecast, By Type, 2020 - 2033 (US$ Million)
11.2.8.4. U.S. Market Size and Forecast, By Indication, 2020 - 2033 (US$ Million)
11.2.8.5. U.S. Market Size and Forecast, By End Use, 2020 - 2033 (US$ Million)
11.2.8.6. U.S. Market Size and Forecast, By Form, 2020 - 2033 (US$ Million)
11.2.9. Canada
11.2.9.1. Overview
11.2.9.2. Market Analysis, Forecast, and Y-O-Y Growth Rate, 2020 - 2033, (US$ Million)
11.2.9.3. Canada Market Size and Forecast, By Type, 2020 - 2033 (US$ Million)
11.2.9.4. Canada Market Size and Forecast, By Indication, 2020 - 2033 (US$ Million)
11.2.9.5. Canada Market Size and Forecast, By End Use, 2020 - 2033 (US$ Million)
11.2.9.6. Canada Market Size and Forecast, By Form, 2020 - 2033 (US$ Million)
11.3. Europe
11.3.1. Overview
11.3.2. Antifibrinolytic Drugs Key Manufacturers in Europe
11.3.3. Europe Market Size and Forecast, By Country, 2020 - 2033 (US$ Million)
11.3.4. Europe Market Size and Forecast, By Type, 2020 - 2033 (US$ Million)
11.3.5. Europe Market Size and Forecast, By Indication, 2020 - 2033 (US$ Million)
11.3.6. Europe Market Size and Forecast, By End Use, 2020 - 2033 (US$ Million)
11.3.7. Europe Market Size and Forecast, By Form, 2020 - 2033 (US$ Million)
11.3.8. Germany
11.3.8.1. Overview
11.3.8.2. Market Analysis, Forecast, and Y-O-Y Growth Rate, 2020 - 2033, (US$ Million)
11.3.8.3. Germany Market Size and Forecast, By Type, 2020 - 2033 (US$ Million)
11.3.8.4. Germany Market Size and Forecast, By Indication, 2020 - 2033 (US$ Million)
11.3.8.5. Germany Market Size and Forecast, By End Use, 2020 - 2033 (US$ Million)
11.3.8.6. Germany Market Size and Forecast, By Form, 2020 - 2033 (US$ Million)
11.3.9. UK
11.3.9.1. Overview
11.3.9.2. Market Analysis, Forecast, and Y-O-Y Growth Rate, 2020 - 2033, (US$ Million)
11.3.9.3. UK Market Size and Forecast, By Type, 2020 - 2033 (US$ Million)
11.3.9.4. UK Market Size and Forecast, By Indication, 2020 - 2033 (US$ Million)
11.3.9.5. UK Market Size and Forecast, By End Use, 2020 - 2033 (US$ Million)
11.3.9.6. UK Market Size and Forecast, By Form, 2020 - 2033 (US$ Million)
11.3.10. France
11.3.10.1. Overview
11.3.10.2. Market Analysis, Forecast, and Y-O-Y Growth Rate, 2020 - 2033, (US$ Million)
11.3.10.3. France Market Size and Forecast, By Type, 2020 - 2033 (US$ Million)
11.3.10.4. France Market Size and Forecast, By Indication, 2020 - 2033 (US$ Million)
11.3.10.5. France Market Size and Forecast, By End Use, 2020 - 2033 (US$ Million)
11.3.10.6. France Market Size and Forecast, By Form, 2020 - 2033 (US$ Million)
11.3.11. Italy
11.3.11.1. Overview
11.3.11.2. Market Analysis, Forecast, and Y-O-Y Growth Rate, 2020 - 2033, (US$ Million)
11.3.11.3. Italy Market Size and Forecast, By Type, 2020 - 2033 (US$ Million)
11.3.11.4. Italy Market Size and Forecast, By Indication, 2020 - 2033 (US$ Million)
11.3.11.5. Italy Market Size and Forecast, By End Use, 2020 - 2033 (US$ Million)
11.3.11.6. Italy Market Size and Forecast, By Form, 2020 - 2033 (US$ Million)
11.3.12. Spain
11.3.12.1. Overview
11.3.12.2. Market Analysis, Forecast, and Y-O-Y Growth Rate, 2020 - 2033, (US$ Million)
11.3.12.3. Spain Market Size and Forecast, By Type, 2020 - 2033 (US$ Million)
11.3.12.4. Spain Market Size and Forecast, By Indication, 2020 - 2033 (US$ Million)
11.3.12.5. Spain Market Size and Forecast, By End Use, 2020 - 2033 (US$ Million)
11.3.12.6. Spain Market Size and Forecast, By Form, 2020 - 2033 (US$ Million)
11.3.13. The Netherlands
11.3.13.1. Overview
11.3.13.2. Market Analysis, Forecast, and Y-O-Y Growth Rate, 2020 - 2033, (US$ Million)
11.3.13.3. The Netherlands Market Size and Forecast, By Type, 2020 - 2033 (US$ Million)
11.3.13.4. The Netherlands Market Size and Forecast, By Indication, 2020 - 2033 (US$ Million)
11.3.13.5. The Netherlands Market Size and Forecast, By End Use, 2020 - 2033 (US$ Million)
11.3.13.6. The Netherlands Market Size and Forecast, By Form, 2020 - 2033 (US$ Million)
11.3.14. Sweden
11.3.14.1. Overview
11.3.14.2. Market Analysis, Forecast, and Y-O-Y Growth Rate, 2020 - 2033, (US$ Million)
11.3.14.3. Sweden Market Size and Forecast, By Type, 2020 - 2033 (US$ Million)
11.3.14.4. Sweden Market Size and Forecast, By Indication, 2020 - 2033 (US$ Million)
11.3.14.5. Sweden Market Size and Forecast, By End Use, 2020 - 2033 (US$ Million)
11.3.14.6. Sweden Market Size and Forecast, By Form, 2020 - 2033 (US$ Million)
11.3.15. Russia
11.3.15.1. Overview
11.3.15.2. Market Analysis, Forecast, and Y-O-Y Growth Rate, 2020 - 2033, (US$ Million)
11.3.15.3. Russia Market Size and Forecast, By Type, 2020 - 2033 (US$ Million)
11.3.15.4. Russia Market Size and Forecast, By Indication, 2020 - 2033 (US$ Million)
11.3.15.5. Russia Market Size and Forecast, By End Use, 2020 - 2033 (US$ Million)
11.3.15.6. Russia Market Size and Forecast, By Form, 2020 - 2033 (US$ Million)
11.3.16. Poland
11.3.16.1. Overview
11.3.16.2. Market Analysis, Forecast, and Y-O-Y Growth Rate, 2020 - 2033, (US$ Million)
11.3.16.3. Poland Market Size and Forecast, By Type, 2020 - 2033 (US$ Million)
11.3.16.4. Poland Market Size and Forecast, By Indication, 2020 - 2033 (US$ Million)
11.3.16.5. Poland Market Size and Forecast, By End Use, 2020 - 2033 (US$ Million)
11.3.16.6. Poland Market Size and Forecast, By Form, 2020 - 2033 (US$ Million)
11.3.17. Rest of Europe
11.3.17.1. Overview
11.3.17.2. Market Analysis, Forecast, and Y-O-Y Growth Rate, 2020 - 2033, (US$ Million)
11.3.17.3. Rest of the Europe Market Size and Forecast, By Type, 2020 - 2033 (US$ Million)
11.3.17.4. Rest of the Europe Market Size and Forecast, By Indication, 2020 - 2033 (US$ Million)
11.3.17.5. Rest of the Europe Market Size and Forecast, By End Use, 2020 - 2033 (US$ Million)
11.3.17.6. Rest of the Europe Market Size and Forecast, By Form, 2020 - 2033 (US$ Million)
11.4. Asia Pacific (APAC)
11.4.1. Overview
11.4.2. Antifibrinolytic Drugs Key Manufacturers in Asia Pacific
11.4.3. APAC Market Size and Forecast, By Country, 2020 - 2033 (US$ Million)
11.4.4. APAC Market Size and Forecast, By Type, 2020 - 2033 (US$ Million)
11.4.5. APAC Market Size and Forecast, By Indication, 2020 - 2033 (US$ Million)
11.4.6. APAC Market Size and Forecast, By End Use, 2020 - 2033 (US$ Million)
11.4.7. APAC Market Size and Forecast, By Form, 2020 - 2033 (US$ Million)
11.4.8. China
11.4.8.1. Overview
11.4.8.2. Market Analysis, Forecast, and Y-O-Y Growth Rate, 2020 - 2033, (US$ Million)
11.4.8.3. China Market Size and Forecast, By Type, 2020 - 2033 (US$ Million)
11.4.8.4. China Market Size and Forecast, By Indication, 2020 - 2033 (US$ Million)
11.4.8.5. China Market Size and Forecast, By End Use, 2020 - 2033 (US$ Million)
11.4.8.6. China Market Size and Forecast, By Form, 2020 - 2033 (US$ Million)
11.4.9. India
11.4.9.1. Overview
11.4.9.2. Market Analysis, Forecast, and Y-O-Y Growth Rate, 2020 - 2033, (US$ Million)
11.4.9.3. India Market Size and Forecast, By Type, 2020 - 2033 (US$ Million)
11.4.9.4. India Market Size and Forecast, By Indication, 2020 - 2033 (US$ Million)
11.4.9.5. India Market Size and Forecast, By End Use, 2020 - 2033 (US$ Million)
11.4.9.6. India Market Size and Forecast, By Form, 2020 - 2033 (US$ Million)
11.4.10. Japan
11.4.10.1. Overview
11.4.10.2. Market Analysis, Forecast, and Y-O-Y Growth Rate, 2020 - 2033, (US$ Million)
11.4.10.3. Japan Market Size and Forecast, By Type, 2020 - 2033 (US$ Million)
11.4.10.4. Japan Market Size and Forecast, By Indication, 2020 - 2033 (US$ Million)
11.4.10.5. Japan Market Size and Forecast, By End Use, 2020 - 2033 (US$ Million)
11.4.10.6. Japan Market Size and Forecast, By Form, 2020 - 2033 (US$ Million)
11.4.11. South Korea
11.4.11.1. Overview
11.4.11.2. Market Analysis, Forecast, and Y-O-Y Growth Rate, 2020 - 2033, (US$ Million)
11.4.11.3. South Korea Market Size and Forecast, By Type, 2020 - 2033 (US$ Million)
11.4.11.4. South Korea Market Size and Forecast, By Indication, 2020 - 2033 (US$ Million)
11.4.11.5. South Korea Market Size and Forecast, By End Use, 2020 - 2033 (US$ Million)
11.4.11.6. South Korea Market Size and Forecast, By Form, 2020 - 2033 (US$ Million)
11.4.12. Australia
11.4.12.1. Overview
11.4.12.2. Market Analysis, Forecast, and Y-O-Y Growth Rate, 2020 - 2033, (US$ Million)
11.4.12.3. Australia Market Size and Forecast, By Type, 2020 - 2033 (US$ Million)
11.4.12.4. Australia Market Size and Forecast, By Indication, 2020 - 2033 (US$ Million)
11.4.12.5. Australia Market Size and Forecast, By End Use, 2020 - 2033 (US$ Million)
11.4.12.6. Australia Market Size and Forecast, By Form, 2020 - 2033 (US$ Million)
11.4.13. Indonesia
11.4.13.1. Overview
11.4.13.2. Market Analysis, Forecast, and Y-O-Y Growth Rate, 2020 - 2033, (US$ Million)
11.4.13.3. Indonesia Market Size and Forecast, By Type, 2020 - 2033 (US$ Million)
11.4.13.4. Indonesia Market Size and Forecast, By Indication, 2020 - 2033 (US$ Million)
11.4.13.5. Indonesia Market Size and Forecast, By End Use, 2020 - 2033 (US$ Million)
11.4.13.6. Indonesia Market Size and Forecast, By Form, 2020 - 2033 (US$ Million)
11.4.14. Thailand
11.4.14.1. Overview
11.4.14.2. Market Analysis, Forecast, and Y-O-Y Growth Rate, 2020 - 2033, (US$ Million)
11.4.14.3. Thailand Market Size and Forecast, By Type, 2020 - 2033 (US$ Million)
11.4.14.4. Thailand Market Size and Forecast, By Indication, 2020 - 2033 (US$ Million)
11.4.14.5. Thailand Market Size and Forecast, By End Use, 2020 - 2033 (US$ Million)
11.4.14.6. Thailand Market Size and Forecast, By Form, 2020 - 2033 (US$ Million)
11.4.15. Philippines
11.4.15.1. Overview
11.4.15.2. Market Analysis, Forecast, and Y-O-Y Growth Rate, 2020 - 2033, (US$ Million)
11.4.15.3. Philippines Market Size and Forecast, By Type, 2020 - 2033 (US$ Million)
11.4.15.4. Philippines Market Size and Forecast, By Indication, 2020 - 2033 (US$ Million)
11.4.15.5. Philippines Market Size and Forecast, By End Use, 2020 - 2033 (US$ Million)
11.4.15.6. Philippines Market Size and Forecast, By Form, 2020 - 2033 (US$ Million)
11.4.16. Rest of APAC
11.4.16.1. Overview
11.4.16.2. Market Analysis, Forecast, and Y-O-Y Growth Rate, 2020 - 2033, (US$ Million)
11.4.16.3. Rest of APAC Market Size and Forecast, By Type, 2020 - 2033 (US$ Million)
11.4.16.4. Rest of APAC Market Size and Forecast, By Indication, 2020 - 2033 (US$ Million)
11.4.16.5. Rest of APAC Market Size and Forecast, By End Use, 2020 - 2033 (US$ Million)
11.4.16.6. Rest of APAC Market Size and Forecast, By Form, 2020 - 2033 (US$ Million)
11.5. Latin America (LATAM)
11.5.1. Overview
11.5.2. Antifibrinolytic Drugs Key Manufacturers in Latin America
11.5.3. LATAM Market Size and Forecast, By Country, 2020 - 2033 (US$ Million)
11.5.4. LATAM Market Size and Forecast, By Type, 2020 - 2033 (US$ Million)
11.5.5. LATAM Market Size and Forecast, By Indication, 2020 - 2033 (US$ Million)
11.5.6. LATAM Market Size and Forecast, By End Use, 2020 - 2033 (US$ Million)
11.5.7. LATAM Market Size and Forecast, By Form, 2020 - 2033 (US$ Million)
11.5.8. Brazil
11.5.8.1. Overview
11.5.8.2. Market Analysis, Forecast, and Y-O-Y Growth Rate, 2020 - 2033, (US$ Million)
11.5.8.3. Brazil Market Size and Forecast, By Type, 2020 - 2033 (US$ Million)
11.5.8.4. Brazil Market Size and Forecast, By Indication, 2020 - 2033 (US$ Million)
11.5.8.5. Brazil Market Size and Forecast, By End Use, 2020 - 2033 (US$ Million)
11.5.8.6. Brazil Market Size and Forecast, By Form, 2020 - 2033 (US$ Million)
11.5.9. Mexico
11.5.9.1. Overview
11.5.9.2. Market Analysis, Forecast, and Y-O-Y Growth Rate, 2020 - 2033, (US$ Million)
11.5.9.3. Mexico Market Size and Forecast, By Type, 2020 - 2033 (US$ Million)
11.5.9.4. Mexico Market Size and Forecast, By Indication, 2020 - 2033 (US$ Million)
11.5.9.5. Mexico Market Size and Forecast, By End Use, 2020 - 2033 (US$ Million)
11.5.9.6. Mexico Market Size and Forecast, By Form, 2020 - 2033 (US$ Million)
11.5.10. Argentina
11.5.10.1. Overview
11.5.10.2. Market Analysis, Forecast, and Y-O-Y Growth Rate, 2020 - 2033, (US$ Million)
11.5.10.3. Argentina Market Size and Forecast, By Type, 2020 - 2033 (US$ Million)
11.5.10.4. Argentina Market Size and Forecast, By Indication, 2020 - 2033 (US$ Million)
11.5.10.5. Argentina Market Size and Forecast, By End Use, 2020 - 2033 (US$ Million)
11.5.10.6. Argentina Market Size and Forecast, By Form, 2020 - 2033 (US$ Million)
11.5.11. Colombia
11.5.11.1. Overview
11.5.11.2. Market Analysis, Forecast, and Y-O-Y Growth Rate, 2020 - 2033, (US$ Million)
11.5.11.3. Colombia Market Size and Forecast, By Type, 2020 - 2033 (US$ Million)
11.5.11.4. Colombia Market Size and Forecast, By Indication, 2020 - 2033 (US$ Million)
11.5.11.5. Colombia Market Size and Forecast, By End Use, 2020 - 2033 (US$ Million)
11.5.11.6. Colombia Market Size and Forecast, By Form, 2020 - 2033 (US$ Million)
11.5.12. Rest of LATAM
11.5.12.1. Overview
11.5.12.2. Market Analysis, Forecast, and Y-O-Y Growth Rate, 2020 - 2033, (US$ Million)
11.5.12.3. Rest of LATAM Market Size and Forecast, By Type, 2020 - 2033 (US$ Million)
11.5.12.4. Rest of LATAM Market Size and Forecast, By Indication, 2020 - 2033 (US$ Million)
11.5.12.5. Rest of LATAM Market Size and Forecast, By End Use, 2020 - 2033 (US$ Million)
11.5.12.6. Rest of LATAM Market Size and Forecast, By Form, 2020 - 2033 (US$ Million)
11.6. Middle East and Africa (MEA)
11.6.1. Overview
11.6.2. Antifibrinolytic Drugs Key Manufacturers in Middle East and Africa
11.6.3. MEA Market Size and Forecast, By Country, 2020 - 2033 (US$ Million)
11.6.4. MEA Market Size and Forecast, By Type, 2020 - 2033 (US$ Million)
11.6.5. MEA Market Size and Forecast, By Indication, 2020 - 2033 (US$ Million)
11.6.6. MEA Market Size and Forecast, By End Use, 2020 - 2033 (US$ Million)
11.6.7. MEA Market Size and Forecast, By Form, 2020 - 2033 (US$ Million)
11.6.8. Saudi Arabia
11.6.8.1. Overview
11.6.8.2. Market Analysis, Forecast, and Y-O-Y Growth Rate, 2020 - 2033, (US$ Million)
11.6.8.3. Saudi Arabia Market Size and Forecast, By Type, 2020 - 2033 (US$ Million)
11.6.8.4. Saudi Arabia Market Size and Forecast, By Indication, 2020 - 2033 (US$ Million)
11.6.8.5. Saudi Arabia Market Size and Forecast, By End Use, 2020 - 2033 (US$ Million)
11.6.8.6. Saudi Arabia Market Size and Forecast, By Form, 2020 - 2033 (US$ Million)
11.6.9. United Arab Emirates
11.6.9.1. Overview
11.6.9.2. Market Analysis, Forecast, and Y-O-Y Growth Rate, 2020 - 2033, (US$ Million)
11.6.9.3. United Arab Emirates Market Size and Forecast, By Type, 2020 - 2033 (US$ Million)
11.6.9.4. United Arab Emirates Market Size and Forecast, By Indication, 2020 - 2033 (US$ Million)
11.6.9.5. United Arab Emirates Market Size and Forecast, By End Use, 2020 - 2033 (US$ Million)
11.6.9.6. United Arab Emirates Market Size and Forecast, By Form, 2020 - 2033 (US$ Million)
11.6.10. Israel
11.6.10.1. Overview
11.6.10.2. Market Analysis, Forecast, and Y-O-Y Growth Rate, 2020 - 2033, (US$ Million)
11.6.10.3. Israel Market Size and Forecast, By Type, 2020 - 2033 (US$ Million)
11.6.10.4. Israel Market Size and Forecast, By Indication, 2020 - 2033 (US$ Million)
11.6.10.5. Israel Market Size and Forecast, By End Use, 2020 - 2033 (US$ Million)
11.6.10.6. Israel Market Size and Forecast, By Form, 2020 - 2033 (US$ Million)
11.6.11. Turkey
11.6.11.1. Overview
11.6.11.2. Market Analysis, Forecast, and Y-O-Y Growth Rate, 2020 - 2033, (US$ Million)
11.6.11.3. Turkey Market Size and Forecast, By Type, 2020 - 2033 (US$ Million)
11.6.11.4. Turkey Market Size and Forecast, By Indication, 2020 - 2033 (US$ Million)
11.6.11.5. Turkey Market Size and Forecast, By End Use, 2020 - 2033 (US$ Million)
11.6.11.6. Turkey Market Size and Forecast, By Form, 2020 - 2033 (US$ Million)
11.6.12. Algeria
11.6.12.1. Overview
11.6.12.2. Market Analysis, Forecast, and Y-O-Y Growth Rate, 2020 - 2033, (US$ Million)
11.6.12.3. Algeria Market Size and Forecast, By Type, 2020 - 2033 (US$ Million)
11.6.12.4. Algeria Market Size and Forecast, By Indication, 2020 - 2033 (US$ Million)
11.6.12.5. Algeria Market Size and Forecast, By End Use, 2020 - 2033 (US$ Million)
11.6.12.6. Algeria Market Size and Forecast, By Form, 2020 - 2033 (US$ Million)
11.6.13. Egypt
11.6.13.1. Overview
11.6.13.2. Market Analysis, Forecast, and Y-O-Y Growth Rate, 2020 - 2033, (US$ Million)
11.6.13.3. Egypt Market Size and Forecast, By Type, 2020 - 2033 (US$ Million)
11.6.13.4. Egypt Market Size and Forecast, By Indication, 2020 - 2033 (US$ Million)
11.6.13.5. Egypt Market Size and Forecast, By End Use, 2020 - 2033 (US$ Million)
11.6.13.6. Egypt Market Size and Forecast, By Form, 2020 - 2033 (US$ Million)
11.6.14. Rest of MEA
11.6.14.1. Overview
11.6.14.2. Market Analysis, Forecast, and Y-O-Y Growth Rate, 2020 - 2033, (US$ Million)
11.6.14.3. Rest of MEA Market Size and Forecast, By Type, 2020 - 2033 (US$ Million)
11.6.14.4. Rest of MEA Market Size and Forecast, By Indication, 2020 - 2033 (US$ Million)
11.6.14.5. Rest of MEA Market Size and Forecast, By End Use, 2020 - 2033 (US$ Million)
11.6.14.6. Rest of MEA Market Size and Forecast, By Form, 2020 - 2033 (US$ Million)
12. Key Vendor Analysis- Antifibrinolytic Drugs Industry
12.1. Competitive Benchmarking
12.1.1. Competitive Dashboard
12.1.2. Competitive Positioning
12.2. Company Profiles
12.2.1. Pfizer Inc.
12.2.2. Novartis AG
12.2.3. Sanofi SA
12.2.4. Takeda Pharmaceutical Company Limited
12.2.5. Viatris Inc.
12.2.6. Bayer AG
12.2.7. Aurobindo Pharma Limited
12.2.8. Ferring Pharmaceuticals
12.2.9. Zydus Lifesciences Limited
12.2.10. ACIC Pharmaceuticals Inc.
12.2.11. Johnson & Johnson (Ethicon – surgical bleeding control)
12.2.12. Octapharma AG
12.2.13. Apotex Inc.
12.2.14. Aspen Pharmacare Holdings Limited
12.2.15. Cipla Limited
12.2.16. Others
13. 360 Degree AnalystView
14. Appendix
14.1. Research Methodology
14.2. References
14.3. Abbreviations
14.4. Disclaimer
14.5. Contact Us
SCOPE OF THE REPORT
The scope of this report covers the market by its major segments, which include as follows:
GLOBAL ANTIFIBRINOLYTIC DRUGS MARKET KEY PLAYERS- DETAILED COMPETITIVE INSIGHTS
- Pfizer Inc.
- Novartis AG
- Sanofi SA
- Takeda Pharmaceutical Company Limited
- Viatris Inc.
- Bayer AG
- Aurobindo Pharma Limited
- Ferring Pharmaceuticals
- Zydus Lifesciences Limited
- ACIC Pharmaceuticals Inc.
- Johnson & Johnson (Ethicon – surgical bleeding control)
- Octapharma AG
- Apotex Inc.
- Aspen Pharmacare Holdings Limited
- Cipla Limited
- Others
GLOBAL ANTIFIBRINOLYTIC DRUGS MARKET, BY TYPE- MARKET ANALYSIS, 2020 - 2033
- Tranexamic Acid
- Aminocaproic Acid
- Aprotinin
- Lysteda
- RiaSTAP
- Fibrinogen
- Trasylol
- Amicor
- Others
GLOBAL ANTIFIBRINOLYTIC DRUGS MARKET, BY INDICATION- MARKET ANALYSIS, 2020 - 2033
- Surgeries
- Gynaecology
- Hereditary Angioedema
- Fibrinolytic Response Testing
- Others
GLOBAL ANTIFIBRINOLYTIC DRUGS MARKET, BY END USE- MARKET ANALYSIS, 2020 - 2033
- Clinics
- Hospitals
- Ambulatory Surgery Centres
- Health Care Specialty Processes
- Others
GLOBAL ANTIFIBRINOLYTIC DRUGS MARKET, BY FORM- MARKET ANALYSIS, 2020 - 2033
- Injectable
- Oral
- Others
GLOBAL ANTIFIBRINOLYTIC DRUGS MARKET, BY REGION- MARKET ANALYSIS, 2020 - 2033
North America
- U.S.
- Canada
Europe
- Germany
- UK
- France
- Italy
- Spain
- The Netherlands
- Sweden
- Russia
- Poland
- Rest of Europe
Asia Pacific
- China
- India
- Japan
- South Korea
- Australia
- Indonesia
- Thailand
- Philippines
- Rest of APAC
Latin America
- Brazil
- Mexico
- Argentina
- Colombia
- Rest of LATAM
The Middle East and Africa
- Saudi Arabia
- UAE
- Israel
- Turkey
- Algeria
- Egypt
- Rest of MEA
Related Reports
Credibility and Certifications
Trusted Insights, Certified Excellence! Coherent Market Insights is a certified data advisory and business consulting firm recognized by global institutes.
ISO 9001:2015
ESOMAR Corporate
GDPR Compliance
D-U-N-S Registered
BBB Accreditation
MRS
